Phase 3 Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have signed a consent form agreeing to take part in the study
- People aged 18 or older
- People who have been diagnosed with hepatocellular carcinoma (a type of liver cancer), confirmed either by a tissue biopsy or by CT or MRI scan using standard diagnostic criteria
- People who have at least one tumor that has not previously been treated
- People whose untreated tumor measures between 3 cm and 8 cm in size
- People whose liver is functioning reasonably well — meaning no yellowing of the skin (jaundice), no fluid buildup in the abdomen (ascites), and no signs of confusion caused by liver failure
- Women who could become pregnant must agree to either avoid heterosexual intercourse or use contraception for at least 3 months after treatment
Who may not be able to join:
- People who have previously received systemic (whole-body) drug treatment for advanced liver cancer
- People whose cancer has spread widely through the liver, spread to other parts of the body, or grown into blood vessels
- People who have liver-related confusion or brain problems caused by liver failure (hepatic encephalopathy)
- People with uncontrolled fluid buildup in the abdomen or around the lungs
- People who have yellowing of the skin or eyes (jaundice)
- People with severely low blood pressure, circulatory collapse, or who need medications to maintain blood pressure
- People with severe heart failure (classified as the most serious level, known as NYHA Class IV)
- People with significantly reduced kidney function, as measured by a specific blood test formula (confirm with trial site)
- People who have had a heart attack within the past 6 months
- People whose life expectancy is less than 12 weeks
- People who have a known allergy or sensitivity to a class of medications called calcium antagonists, or other reasons they cannot safely receive the drugs being studied
- People who, for reasons such as language barriers, psychological conditions, or dementia, would be unable to follow the study procedures
- People who are pregnant, breastfeeding, or planning to become pregnant during treatment or within at least 3 months after treatment
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Fahim Ebrahimi, PD Dr., University Hospital, Basel, Switzerland
Phone: +41 61 777 74 00
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
complete response rate (CRR); progression-free survival (PFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.